ChemoMetec

Earnings Release • Jan 28, 2022

ANNOUNCEMENT NO. 218 28 January 2022

Revenue and EBITDA guidance raised

In the first half of the financial year 2021/22, ChemoMetec continued its positive development, and sales and order intake developed significantly better than expected.

Based on the above, ChemoMetec now expects revenue in the financial year 2021/22 in the DKK 385-395 million range, up from DKK 370-380 million, and EBITDA is expected to be in DKK 195-200 million range, up from DKK 175-180 million.

For further information

Steen Søndergaard, CEO, ChemoMetec A/S Phone: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to www.chemometec.com.

ChemoMetec A/S Gydevang 43 DK-3450 Allerød Denmark

Phone +45 4813 1020 Fax +45 4813 1021 www.chemometec.com Company reg. (CVR) No.

1982.8131